Does LFST pay a dividend and is it safe?

LifeStance Health Group Inc. (LFST) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / LFST / dividends

OPCH (74) HIMS (60) CHE (83) AVAH (65) ⌘ Pro Terminal →

LifeStance Health Group Inc. (LFST) Dividend Safety Gauge & 10-Year DRIP Compounder

$13.26 -1.04% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.21

LifeStance Health Group Inc. (LFST) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 67/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.6% avg 90D alpha vs SPY) →

ROARABLE C+ • HOLD / WATCH Cap $5.12B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LFST Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LFST stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, LifeStance Health Group Inc. (NASDAQ: LFST) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $13.26 (-1.04% 1D, market cap $5.12B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, LFST ranks #105 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LFST compare to OPCH and HIMS in the Health Care sector?

▼

Within the Health Care sector (Medical/Nursing Services), LFST carries a Roarable C+ (67/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 1.2%. By comparison, OPCH (Option Care Health Inc.) holds a B grade (74/100 RQD, P/E 23.0x, ROIC 11.9%, cap $4.77B) and HIMS (Hims & Hers Health Inc.) posts a C- grade (60/100 RQD, P/E 53.9x, ROIC 8.4%, cap $6.46B). Among the 5-stock peer group, OPCH leads on earnings multiple (23.0x) while CHE leads on capital efficiency (23.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LFST?

▼

Per LFST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001845257), LifeStance Health Group Inc. generated $1.42B in revenue (+13.9% YoY), $9.7M in net income, and $110.0M in free cash flow against $2.20B in total assets and $265.9M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $13.21 (-0.38%)🧬 Cannibal Buyback (-0.68% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 7.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 67/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.6% avg 90D alpha vs SPY • 56.4% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+4.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LFST)Realized 20D OHLCV Swing Band: ±6.8%

Deterministic 5-Pillar Attribution (67/100 Composite)

🔍 WHY LFST SCORES 67/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (27% of score)

Altman Z-Score 4.84 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Whale & Options Positioning+16/20 pts (24% of score)

20D Institutional Volume Accumulation (±6.8% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution10/20 pts (-10 pt drag)

Cannibal Buyback (-0.68% YoY Shares) & executive Form 4 sales trim 10 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$12.32-0.8% Next Q

Q2 (-2Q)

Grade C+$12.22+7.2% Next Q

Q3 (-1Q)

Grade C+$13.10+1.2% Next Q

Current

Grade C+$13.26+1.6% Hist 90D α

Trajectory: C (59) → C+ (67)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the LFST Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 67/100 (C+) score, LFST faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-0.68% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($12.53) or 200D SMA ($9.40) invalidates the momentum regime and cuts Target Base ($13.80) toward Bear Floor ($10.76).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LFST• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LFST Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 67%NO 33%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (9.4% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $24,557

Est. Year-10 Shareholder Yield: $442/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.9K

Yr 1

$12.0K

Yr 2

$13.1K

Yr 3

$14.3K

Yr 4

$15.7K

Yr 5

$17.1K

Yr 6

$18.8K

Yr 7

$20.5K

Yr 8

$22.4K

Yr 9

$24.6K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in LFST & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on LFST and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LFST // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +82.39%▲ ASCENDING CHANNEL

2026-11-03O $13.63H $13.63L $13.26C $13.26VOL 2.30M

RES: $14.96SUP: $12.06SMA50: $12.53SMA200: $9.40

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LFST Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LFST Butterfly Map → + Track LFST →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

48.0%/yr Implied 5Y Growth

vs. +13.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LFST today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LFST. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LFST today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LFST)

Health Care Rank #105 of 1016 ⚔️ OPCH vs LFST Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LFST vs. OPCH, HIMS, CHE, AVAH)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, LifeStance Health Group Inc. (LFST) ranks #105 by composite RQD confidence (67/100, grade C+) and #162 by equity capitalization ($5.12B). Within this direct 5-issuer industry benchmark cohort, OPCH leads on earnings valuation at 23.0x trailing P/E, while CHE leads on capital efficiency and profitability with 23.4% ROIC and 32.5% gross margin. CHE currently holds the highest overall quantitative score in the immediate peer group at 83/100 (A-) compared with LFST at 67/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LFST ACTIVE LifeStance Health Group Inc.	C+	67/100	—	—	1.2%	-1.04%	$5.12B	Benchmark Subject
OPCH Option Care Health Inc.	B	74/100	23.0x	19.3%	11.9%	-0.44%	$4.77B	/opch-vs-lfst →
HIMS Hims & Hers Health Inc.	C-	60/100	53.9x	73.8%	8.4%	-8.81%	$6.46B	/hims-vs-lfst →
CHE Chemed Corp	A-	83/100	—	32.5%	23.4%	+1.40%	$6.96B	/che-vs-lfst →
AVAH Aveanna Healthcare Holdings Inc.	C	65/100	—	33.3%	15.7%	-0.30%	$2.87B	/avah-vs-lfst →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001845257

In its most recent audited fiscal period (FY2025, filed 2025-12-31), LifeStance Health Group Inc. (LFST) reported GAAP revenue of $1.42B (+13.9% vs. FY2024 revenue of $1.25B , and +34.9% cumulative change since FY2023) , GAAP net income of $9.7M, operating cash flow of $146.2M, and free cash flow of $110.0M (+28.4% YoY). On the balance sheet, LFST closed FY2025 with $2.20B in total assets against $265.9M in total debt (Altman Z-Score: 4.84, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.42B	$9.7M	$146.2M	$110.0M	$2.20B	$265.9M
FY2024 (FY)	2024-12-31	$1.25B	-$57.4M	$107.3M	$85.7M	$2.12B	$279.8M
FY2023 (FY)	2023-12-31	$1.06B	-$186.3M	-$16.9M	-$16.9M	—	—

3. LFST Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LFST stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does LFST compare to OPCH and HIMS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for LFST?

Where is LFST trading relative to its 50-day, 200-day, and 52-week technical levels?

LFST last traded at $13.26 (-1.04% on volume of 3,364,949 shares), positioning the stock +5.83% above its 50-day simple moving average ($12.53) and +41.06% above its 200-day simple moving average ($9.40). Across its 52-week range of $4.77 to $13.76, LFST sits at the 94.4% percentile with a 14-day RSI of 62.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.8% ($12.36 to $14.16).

Direct Sub-Reports: LFST RQD Cockpit LFST 12M Forecast LFST Earnings & Move LFST Dividends & DRIP LFST Insiders & 13F LFST Whale Options LFST Profit Sankey LFST News & Why

ROARABLE RATING BRIEF • RQD 67/100 (C+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

LFST — LifeStance Health Group Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:20:38Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

LFST scores 68 out of 100, a letter grade of C+, with the verdict "Roarable Hold — Upper Neutral / Watch for Breakout." The five pillars are: Fundamental Cash Engine at 10 of 20 (ROIC 1.2%; FCF yield 2.11%), Whale 13F Flow at 17 of 20 (institutional accumulation and options positioning), Insider Conviction at 10 of 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 13 of 20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 18 of 20 (Altman Z 4.84; Piotroski F 8/9; Debt/Equity 0.17). The profile is uneven: the balance sheet and institutional-flow pillars carry the score, while the cash-generation and insider-conviction pillars are weak. For a prospective investor, the rating points to a stock with low financial-distress risk and visible institutional interest, but with thin returns on capital and limited insider signal, so the rating frames the name as a hold with upside contingent on a shift in the weaker pillars rather than a clear buy case.

2. Business Model, Unit Margins & SEC Financial Trajectory

LifeStance Health Group Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Nursing Services industry. The company reported FY 2025 revenue of $1.42B.

Revenue grew from $1.06B in FY 2023 to $1.42B in FY 2025, and operating income moved from -$189.1M to $24.1M over the same span. Per the market data, operating margin is 1.7%, net margin 0.7%, and gross margin 0%, with ROIC at 1.2%. The Altman Z-Score is 4.84 and the Piotroski F-Score is 8 of 9, and Debt/Equity is 0.17, which together describe a balance sheet with low distress indicators. Net income remains thin relative to revenue, so the improvement is recent and has not yet translated into strong returns.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: Balance-sheet strength (Altman Z 4.84, Piotroski F 8/9, Debt/Equity 0.17) and 17 of 20 institutional-flow score support the rating. With Fundamental Cash Engine at 10/20 (ROIC 1.2%, FCF yield 2.11%) and Institutional Whale Flow at 16/20, sustained execution supports upside toward the top of the $4.77 – $13.76 52-week range.
🐻 Primary Bear Case: ROIC of 1.2% and a 95.3 EV/EBITDA multiple leave thin returns against a premium valuation. Investors must weigh current valuation and 95.3x EV/EBITDA against 1.7% operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Nursing Services (Health Care), LFST carries a macro regime beta of 1.00 and gross margin of —.

Key Question #1: What drove the shift from FY 2024 net loss of -$57.4M to FY 2025 net income of $9.7M, and is it repeatable?
Key Question #2: What is the basis for the 95.3 EV/EBITDA multiple relative to the 1.2% ROIC?
Key Question #3: What did the Q2 2026 earnings call disclose that prompted the KeyBanc target increase and the 5.1% decline noted by GuruFocus?

LFST Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for LifeStance Health Group Inc. (LFST) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LFST Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 20h ago

Is LifeStance Health Group (LFST) A Bargain on Cash Flow?

Yahoo Finance report covering LifeStance Health Group Inc. (LFST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Investing.com • 23h ago

KeyBanc raises Lifestance Health stock price target on specialty care growth

Investing.com report covering LifeStance Health Group Inc. (LFST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

Transcript: LifeStance Health Gr Q2 2026 Earnings Conference Call

Benzinga report covering LifeStance Health Group Inc. (LFST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH GuruFocus • 1d ago

LifeStance Health Group Inc (LFST) Shares Fall 5.1% -- GF Value Says Still Overvalued

GuruFocus report covering LifeStance Health Group Inc. (LFST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

LifeStance to Host Third Quarter 2026 Earnings Conference Call on November 5, 2026

Yahoo Finance report covering LifeStance Health Group Inc. (LFST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

What Is Drawing Fresh Attention To LifeStance Health Group (LFST)?

Simply Wall St report covering LifeStance Health Group Inc. (LFST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

In one depression-treatment analysis, near-daily suicidal thoughts fell from 13% to 2%.

Stock Titan report covering LifeStance Health Group Inc. (LFST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

LifeStance Health Group, Inc. (LFST) Stock Forecasts

Yahoo Finance report covering LifeStance Health Group Inc. (LFST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LFST Bull vs. Bear Conversation Board — What's Your Call at $13.26?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LFST 🐻 33% BEARISH CONVICTION

MA MacroHawk_NYC Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $17.02 (+27.0%)

📌 Pinned Debate

Balance-sheet strength (Altman Z 4.84, Piotroski F 8/9, Debt/Equity 0.17) and 17 of 20 institutional-flow score support the rating.

Balance-sheet strength (Altman Z 4.84, Piotroski F 8/9, Debt/Equity 0.17) and 17 of 20 institutional-flow score support the rating.. When you look under the hood at LFST, Fundamental Cash Engine is 10/20 with 0.0% gross margins and 1.2% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (16/20) has been quietly accumulating below $13.76. My 12M target is $17.02.

RetailWhale_TX 🐂 BULL

Both sides have a point here — LFST's 18/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

ME MeanReversion_88 Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $11.39 (-15.0%)

Spot @ $13.40

ROIC of 1.2% and a 95.3 EV/EBITDA multiple leave thin returns against a premium valuation.

ROIC of 1.2% and a 95.3 EV/EBITDA multiple leave thin returns against a premium valuation.. Look at the math on LFST: paying current EV/EBITDA multiples for 1.2% ROIC and 1.7% operating margins leaves zero margin of safety if Medical/Nursing Services demand softens. I'd wait for a retest of $11.79 before getting long.